CA1214122A - Poliovirus-neutralizing-monoclonal antibodies and hybridomas secreting said antibodies - Google Patents
Poliovirus-neutralizing-monoclonal antibodies and hybridomas secreting said antibodiesInfo
- Publication number
- CA1214122A CA1214122A CA000441462A CA441462A CA1214122A CA 1214122 A CA1214122 A CA 1214122A CA 000441462 A CA000441462 A CA 000441462A CA 441462 A CA441462 A CA 441462A CA 1214122 A CA1214122 A CA 1214122A
- Authority
- CA
- Canada
- Prior art keywords
- poliovirus
- antibodies
- antigenicity
- particles
- active against
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 30
- 230000003248 secreting effect Effects 0.000 title abstract description 11
- 241000991587 Enterovirus C Species 0.000 claims abstract description 43
- 210000004027 cell Anatomy 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 21
- 241001465754 Metazoa Species 0.000 claims abstract description 9
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 9
- 210000000234 capsid Anatomy 0.000 claims abstract description 9
- 201000000050 myeloid neoplasm Diseases 0.000 claims abstract description 9
- 210000004989 spleen cell Anatomy 0.000 claims abstract description 8
- 239000002245 particle Substances 0.000 claims description 36
- 241000700605 Viruses Species 0.000 claims description 31
- 239000000427 antigen Substances 0.000 claims description 14
- 230000002458 infectious effect Effects 0.000 claims description 10
- 230000001413 cellular effect Effects 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 230000000890 antigenic effect Effects 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 230000004927 fusion Effects 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 230000003472 neutralizing effect Effects 0.000 abstract description 9
- 230000006698 induction Effects 0.000 abstract description 5
- 230000036039 immunity Effects 0.000 abstract description 4
- 230000000154 anti-poliomyelitic effect Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 206010003445 Ascites Diseases 0.000 description 16
- 239000007788 liquid Substances 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 9
- 230000003053 immunization Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 210000004754 hybrid cell Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000001738 isopycnic centrifugation Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229940072417 peroxidase Drugs 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100036850 C-C motif chemokine 23 Human genes 0.000 description 1
- 102000012000 CXCR4 Receptors Human genes 0.000 description 1
- 108010061299 CXCR4 Receptors Proteins 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229940124867 Poliovirus vaccine Drugs 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000538 anti-polioviral effect Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 229950011321 azaserine Drugs 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- KKNIUBFRGPFELP-UHFFFAOYSA-N secretolin Chemical compound N=1C=CNC=1CC(N)C(=O)NC(CO)C(=O)NC(CC(O)=O)C(=O)NCC(=O)NC(C(C)O)C(=O)NC(C(=O)NC(C(=O)NC(CO)C(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC(O)=O)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NCC(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(O)=O)C(C)O)CC1=CC=CC=C1 KKNIUBFRGPFELP-UHFFFAOYSA-N 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1009—Picornaviridae, e.g. hepatitis A virus
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8219338 | 1982-11-18 | ||
| FR8219338A FR2536414A1 (fr) | 1982-11-18 | 1982-11-18 | Anticorps monoclonaux neutralisants a l'egard des structures peptidiques du poliovirus responsables de l'induction d'une immunite antipoliomyelitique, hybridomes secreteurs de tels anticorps et procede pour leur production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1214122A true CA1214122A (en) | 1986-11-18 |
Family
ID=9279297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000441462A Expired CA1214122A (en) | 1982-11-18 | 1983-11-18 | Poliovirus-neutralizing-monoclonal antibodies and hybridomas secreting said antibodies |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0112741A1 (enrdf_load_stackoverflow) |
| JP (1) | JPS59113888A (enrdf_load_stackoverflow) |
| CA (1) | CA1214122A (enrdf_load_stackoverflow) |
| FR (1) | FR2536414A1 (enrdf_load_stackoverflow) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0169146A3 (en) * | 1984-07-20 | 1988-07-20 | Merck & Co. Inc. | Monoclonal antibodies directed against the cellular receptor of human rhinovirus |
| NZ218050A (en) * | 1985-11-13 | 1989-05-29 | Wistar Inst | Test for the presence of htlv-1v |
| JPH01131126A (ja) * | 1987-09-02 | 1989-05-24 | Synbiotics Corp | 抗ウィルス薬としての抗ウィルスネオ抗原抗体及びそれにより誘導された抗イデオタイプ抗体 |
-
1982
- 1982-11-18 FR FR8219338A patent/FR2536414A1/fr active Granted
-
1983
- 1983-11-18 JP JP58216432A patent/JPS59113888A/ja active Pending
- 1983-11-18 EP EP83402230A patent/EP0112741A1/fr not_active Withdrawn
- 1983-11-18 CA CA000441462A patent/CA1214122A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JPS59113888A (ja) | 1984-06-30 |
| FR2536414B1 (enrdf_load_stackoverflow) | 1985-04-26 |
| EP0112741A1 (fr) | 1984-07-04 |
| FR2536414A1 (fr) | 1984-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Walsh et al. | Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein | |
| Wickramasinghe et al. | Avian reovirus proteins associated with neutralization of virus infectivity | |
| Jiménez et al. | Critical epitopes in transmissible gastroenteritis virus neutralization | |
| Thorley-Lawson et al. | Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity. | |
| Taniguchi et al. | Preparation and characterization of neutralizing monoclonal antibodies with different reactivity patterns to human rotaviruses | |
| Taniguchi et al. | Cross-reactive neutralization epitopes on VP3 of human rotavirus: analysis with monoclonal antibodies and antigenic variants | |
| Halk et al. | Production of monoclonal antibodies against three ilarviruses and alfalfa mosaic virus and their use in serotyping | |
| Yousef et al. | Derivation and biochemical characterization of an enterovirus group-specific monoclonal antibody | |
| Burns et al. | Functional and topographical analyses of epitopes on the hemagglutinin (VP4) of the simian rotavirus SA11 | |
| Ikuta et al. | Identification with monoclonal antibodies of glycoproteins of Marek's disease virus and herpesvirus of turkeys related to virus neutralization | |
| CA1217422A (en) | Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors | |
| Carrascosa et al. | African swine fever virus attachment protein | |
| Yamanishi et al. | Antigenic differences between two viruses, isolated in Japan and Korea, that cause hemorrhagic fever with renal syndrome | |
| ES2297855T3 (es) | Anticuerpos monoclonales contra la hepatitis b. | |
| Nitayaphan et al. | Neutralizing monoclonal antibodies to Theiler's murine encephalomyelitis viruses | |
| CN104220090A (zh) | 肠道病毒71型的特异性抗体及其用途 | |
| USRE32833E (en) | Screening vaccines and immunization process | |
| Brown et al. | Localization of an immunodominant domain on baculovirus-produced parvovirus B19 capsids: correlation to a major surface region on the native virus particle | |
| US4490358A (en) | Screening vaccines and immunization process | |
| Cheng et al. | Detection of the readthrough protein of barley yellow dwarf virus | |
| KR101865878B1 (ko) | 넙치랩도바이러스에 특이적인 단클론항체 및 이의 용도 | |
| CA1214122A (en) | Poliovirus-neutralizing-monoclonal antibodies and hybridomas secreting said antibodies | |
| Forghani et al. | Epitopes functional in neutralization of varicella-zoster virus | |
| Zheng et al. | Comparative studies of the antigenic polypeptide species VP4, VP6, and VP7 of three strains of bovine rotavirus | |
| Franko et al. | Monoclonal antibodies specific for Hantaan virus. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |